Table 1 The clinicopathological characteristics of the TCGA included patients
Characteristic | Cluster 1 | Cluster 2 | P |
|---|---|---|---|
n | 187 | 211 | |
Age, mean ± SD | 67.46 ± 11.29 | 68.11 ± 9.79 | 0.536 |
BMI, mean ± SD | 27.1 ± 5.78 | 26.84 ± 5.57 | 0.670 |
Sex, n (%) | 0.271 | ||
Female | 44 (11.1%) | 61 (15.3%) | |
Male | 143 (35.9%) | 150 (37.7%) | |
Smoking history, n (%) | 0.071 | ||
No | 124 (32.2%) | 156 (40.5%) | |
Yes | 58 (15.1%) | 47 (12.2%) | |
Lymphatic vessel invasion, n (%) | 0.913 | ||
Yes | 56 (20.7%) | 67 (24.8%) | |
No | 69 (25.6%) | 78 (28.9%) | |
WHO grade, n (%) | < 0.001 | ||
High | 170 (43%) | 207 (52.4%) | |
Low | 16 (4.1%) | 2 (0.5%) | |
AJCC stage, n (%) | 0.114 | ||
AJCC stage III–IV | 67 (16.9%) | 59 (14.9%) | |
AJCC stage I–II | 119 (30.1%) | 151 (38.1%) | |
Distant metastasis, n (%) | 0.528 | ||
M0 | 92 (45.5%) | 100 (49.5%) | |
M1 | 6 (3%) | 4 (2%) | |
Lymph node metastasis, n (%) | 0.902 | ||
N+ | 58 (16.2%) | 69 (19.3%) | |
N0 | 108 (30.3%) | 122 (34.2%) | |
T stage, n (%) | 0.347 | ||
T2_4 | 112 (30.5%) | 137 (37.3%) | |
Ta_1 | 60 (16.3%) | 58 (15.8%) | |
Overall survival, n (%) | 0.005 | ||
Alive | 119 (29.9%) | 104 (26.1%) | |
Dead | 68 (17.1%) | 107 (26.9%) | |
Cancer-specific survival, n (%) | 0.003 | ||
Alive | 139 (36.2%) | 125 (32.6%) | |
Dead | 43 (11.2%) | 77 (20.1%) | |
Progression-free survival, n (%) | 0.005 | ||
No | 120 (30.2%) | 105 (26.4%) | |
Yes | 67 (16.8%) | 106 (26.6%) |